Risperidone use in preschool children with aggressive and destructive behavioral symptoms

Amaç: Temel olarak agresif ve yıkıcı davranışsal belirtiler ile başvuran okul öncesi çağdaki çocuklarda risperidon kullanım yaygınlığı ve özelliklerini araştırmayı amaçladık. Yöntem: Bu geriye dönük dosya tarama çalışmasında, hastaların tıbbi kayıtları yaş, cinsiyet, birincil ve eş tanılar, risperidon dozu ve tedavi süresi açısından gözden geçirildi. Risperidon dozu ve tedavi süresi birincil tanılar arasında karşılaştırıldı. Bulgular: Risperidonun 2790 çocukta kullanım yaygınlığı %18.5’ti (s=516). Ortalama yaş 4.86±1.12 yıl idi. Bu hastaların %74.4’ünde bir yıkıcı davranış bozukluğu (YDB) birincil tanısı vardı. Risperidon ortalama başlangıç dozu 0.35 mg/gün ve ortalama idame dozu 0.52 mg/gün idi. Tedavinin ortalama süresi 4.9 ay idi. Zeka geriliği (ZG) olan hastalarda, YDB olan hastalara göre, başlangıç ve sürdürme dozları anlamlı olarak daha yüksek ve tedavi süresi anlamlı olarak daha uzundu. Tartışma: Okul öncesi çocuklarda, risperidon MR olan hastalarda daha yüksek dozlarla ve daha uzun süreli tedavi ile azaltılabilen agresif ve yıkıcı davranışsal belirtilerini kontrol etmek için sıklıkla kullanılır Agresif ve yıkıcı davranışları olan çocuklar için kanıta dayalı tedavi yöntemlerinin geliştirilmesi kontrollü çalışmalara ve onların klinik pratiğe uygunluğunun onayını gerektirir.

Agresif ve yıkıcı davranışsal belirtileri olan okul öncesi çocuklarda risperidon kullanımı

Objective: We aimed to investigate the prevalence and mode of risperidone use in preschool aged children admitted with a chief complaint of aggressive and destructive behavioral symptoms. Methods: In this retrospective chart review study, medical records of the patients were reviewed for age, gender, primary and comorbid diagnoses, dosage and duration of risperidone treatment. Dosage and duration of risperidone treatment were compared among primary diagnoses. Results: In 2790 children prevalence of risperidone use was 18.5% (n=516). Mean age was 4.86±1.12 years. Of these patients, %74.4 had primary diagnosis of a disruptive behavior disorder (DBD). Mean starting dosage of risperidone was 0.35 mg/day and mean maintenance dosage was 0.52 mg/day. The mean length of treatment was 4.9 months. Starting and maintenance doses were significantly higher and treatment duration was longer in patients with mental retardation (MR) than in those with DBDs. Conclusion: In preschoolers, risperidone is frequently used to control aggressive and destructive behavioral symptoms which may improve with higher doses and longer treatment in those with MR. The development of evidence-based treatment modalities for children with aggressive and destructive behaviors necessitates controlled studies and confirmation of their pertinence to clinical practice.

___

  • 1. Dekker MC, Koot HM, Van der Ende J, Verhulst FC. Emotional and behavioral problems in chil- dren and adolescents with and without intellectual disability. J Child Psychol Psychiatry 2002; 43:1087-1098.
  • 2. Egger HL, Angold A. Common emotional and behavioral disorders in preschool children: pre- sentation, nosology, and epidemiology. J Child Psychol Psychiatry 2006; 47:313-337.
  • 3. Lavigne JV, Cicchetti C, Gibbons RD, Binns HJ, Larsen L, DeVito C. Oppositional defiant disorder with onset in preschool years: longitudinal stability and pathways to other disorders. J Am Acad Child Adolesc Psychiatry 2001; 40:1393-1400.
  • 4. Robinson M, Oddy WH, Li J, Kendall GE, de Klerk NH, Silburn SR, et al. Pre- and postnatal influ- ences on preschool mental health: a large-scale cohort study. J Child Psychol Psychiatry 2008; 49(10):1118-1128.
  • 5. Stadler C, Bolten M, Schmeck K. Pharmacotherapeutic intervention in impulsive preschool children: The need for a comprehensive therapeutic approach. Child Adolesc Psychiatry Ment Health 2011; 5(1):11.
  • 6. Coskun M, Zoroglu SS, Ozturk MM. Risperidone treatment in preschool children with disruptive be- havior disorders: a chart review study. Bulletin of Clinical Psychopharmacology 2011; 21(1):33-41.
  • 7. Langworthy-Lam KS, Aman MG, Van Bourgon- dien ME. Prevalence and patterns of use of psychoactive medicines in individuals with autism in the Autism Society of North Carolina. J Child Adolesc Psychopharmacol. 2005; 12:311-321.
  • 8. Matson JL, Bamburg JW, Mayville EA, Pinkston J, Bielecki J, Kuhn D, et al. Psychopharmacology and mental retardation: a 10 year review (1990- 1999). Res Dev Disabil 2000; 21:263-296.
  • 9. Jensen PS, Bhatara VS, Vitiello B, Hoagwood K, Feil M, Burke LB. Psychoactive medication pre- scribing practices for US children: gaps between research and clinical practice. J Am Acad Child Adolesc Psychiatry 1999; 38:557-565.
  • 10. Masi G, Cosenza A, Mucci M, Brovedani P. Open trial of risperidone in 24 young children with per- vasive developmental disorders. J Am Acad Child Adolesc Psychiatry 2001; 40(10):1206-1214.
  • 11. Pringsheim T, Panagiotopoulos C, Davidson J, Ho J, CAMESA Guideline Group. Evidence-based recommendations for monitoring safety of second generation antipsychotics in children and youth. J Can Acad Child Adolesc Psychiatry 2011; 20(3):218-233.
  • 12. Pandina GJ, Aman MG, Findling RL. Risperidone in the management of disruptive behavior disor- ders. J Child Adolescent Psychopharmacol 2006; 4:379-392.
  • 13. Crystal S, Olfson M, Huang C, Pincus H, Gerhard T. Broadened use of atypical antipsychotics: safety, effectiveness, and policy challenges. Health Aff (Millwood) 2009; 28(5):w770-781.
  • 14. Lohr WD, Honaker J. Atypical antipsychotics for the treatment of disruptive behavior. Pediatr Ann 2013; 42(2):72-77.
  • 15. Harrison JN, Cluxton-Keller F, Gross D. Anti- psychotic medication prescribing trends in chil- dren and adolescents. J Pediatr Health Care 2012; 26(2):139-145.
  • 16. Hässler F, Reis O. Pharmacotherapy of disruptive behavior in mentally retarded subjects: A review of the current literature. Dev Disabil Res Rev 2010; 16(3):265-272.
  • 17. Erdogan A, Atasoy N, Akkurt H, Ozturk D, Kara- ahmet E, Yalug I, et al. Risperidone and liver function tests in children and adolescents: a short- term prospective study. Prog Neuropsychophar- macol Biol Psychiatry 2008; 32(3):849-857.
  • 18. Ercan ES, Basay BK, Basay O, Durak S, Ozbaran B. Risperidone in the treatment of conduct disor- der in preschool children without intellectual dis- ability. Child Adolesc Psychiatry Ment Health 2011; 5(1):10.
  • 19. Gleason MM, Egger HL, Emslie GJ, Greenhill LL, Kowatch RA, Lieberman AF, et al. Psychophar- macological treatment for very young children: contexts and guidelines. J Am Acad Child Adolesc Psychiatry 2007; 46(12):1532-1572.
  • 20. Pathak S, Arszman SP, Danielyan A, Johns ES, Smirnov A, Kowatch RA. Psychotropic utilization and psychiatric presentation of hospitalized very young children. J Child Adolesc Psychopharmacol 2004; 14:433-442.
  • 21. Luby JL, Stalets MM, Belden AC. Psychotropic prescriptions in a sample including both healthy and mood and disruptive disordered preschoolers: relationships to diagnosis, impairment, prescriber type, and assessment methods. J Child Adolesc Psychopharmacol 2007; 17(2):205-215.
  • 22. Olfson M, Crystal S, Huang C, Gerhard T. Trends in antipsychotic drug use by very young, privately insured children. J Am Acad Child Adolesc Psychiatry 2010; 49:13-23.
  • 23. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, fourth ed. (DSM-IV). Washington, DC: American Psychiatric Press, 1994.
  • 24. Turgay A, Binder C, Snyder R, Fisman S. Long- term safety and efficacy of risperidone for the treatment of disruptive behavior disorders in children with subaverage IQs. Pediatrics 2002; 110(3):e34.
  • 25. Connor DF, Boone RT, Steingard RJ. Psycho- pharmacology and aggression: II. A meta-analysis of nonstimulant medication effects on overt aggression-related behaviors in youth with SED. J Emot Behav Disord 2003; 11:157-168.
  • 26. Reyes M, Buitelaar J, Toren P, Augustyns I, Eerdekens M. A randomized, double-blind, place- bo-controlled study of risperidone maintenance treatment in children and adolescents with disrupt- tive behavior disorders. Am J Psychiatry 2006; 163:402-410.
  • 27. DeBar LL, Lynch F, Powell J, Gale J. Use of psychotropic agents in preschool children: as- sociated symptoms, diagnoses, and health care services in a health maintenance organization. Arch Pediatr Adolesc Med 2003; 157:150-157.
  • 28. Rappley MD, Mullan PB, Alvarez FJ, Eneli IU, Wang J, Gardiner JC. Diagnosis of attention- deficit/hyperactivity disorder and use of psychotro- pic medication in very young children. Arch Pediatr Adolesc Med 1999; 153:1039-1045.
  • 29. Rappley MD, Eneli IU, Mullan PB, Alvarez FJ, Wang J, Luo Z, et al. Patterns of psychotropic medication use in very young children with atten- tion-deficit hyperactivity disorder. J Dev Behav Pediatr. 2002;23:23–30.
  • 30. Olfson M, Blanco C, Liu SM, Wang S, Correll CU. National trends in the office-based treatment of children, adolescents, and adults with antipsycho- tics. Arch Gen Psychiatry. 2012;69(12):1247- 1256.
  • 31. Pathak P, West D, Martin BC, Helm ME, Hender- son C. Evidence-based use of second-generation antipsychotics in a state Medicaid pediatric popu- lation, 2001-2005. Psychiatr Serv 2010; 61(2):123-129.
  • 32. Kölch M, Märsch C, Fegert JM, Lippert HD. Clinical trials with minors in Germany--effects of the 12th amendment to the German Drug Code on the numbers of applications to Institutional Review Boards (IRB). Gesundheitswesen 2009; 71(3):127-133.
  • 34. Biederman J, Mick E, Hammerness P, Harpold T, Aleardi M, Dougherty M, et al. Open-label, 8-week trial of olanzapine and risperidone for the treatment of bipolar disorder in preschool-age children. Biol Psychiatry 2005; 58:589-594.
  • 35. Cesena M, Gonzalez-Heydrich J, Szigethy E, Kohlenberg TM, DeMaso DR. A case series of eight aggressive young children treated with rispe- ridone. J Child Adolesc Psychopharmacol 2002; 12:337-345.
  • 36. Luby J, Mrakotsky C, Stalets MM, Belden A, Heffelfinger A, Williams M, et al. Risperidone in Preschool Children with Autistic Spectrum Disor- ders: An Investigation of Safety and Efficacy. J Child Adolescent Psychopharmacol 2006; 16:575-587.
  • 37. Aman MG, De Smedt G, Derivan A, Lyons B, Findling RL, Risperidone Disruptive Behavior Study Group. Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. Am J Psychiatry 2002; 159:1337-1346.
  • 38. Canitano R, Scandurra V. Risperidone in the treatment of behavioral disorders associated with autism in children and adolescents. Neuro- psychiatr Dis Treat 2008; 4(4):723-730.
Anadolu Psikiyatri Dergisi-Cover
  • ISSN: 1302-6631
  • Yayın Aralığı: Yılda 6 Sayı
  • Başlangıç: 2000
  • Yayıncı: -
Sayıdaki Diğer Makaleler

Bağlanma ve obsesif kompulsif belirtiler arasındaki ilişkide obsesif inançların aracı rolünün incelenmesi

SEVGİNAR VATAN

Psikiyatri kliniğinde yatan hastalarda intihar olasılığı ve etkileyen etkenler

SELMA SABANCIOĞULLARI, DİLEK AVCI, Selma DOĞAN, MERAL KELLECİ, ELVAN EMİNE ATA

Üniversite öğrencilerinde riskli davranışlar ile çocukluk çağı istismar, dürtüsellik ve riskli davranışlar arasındaki ilişki

Özge EREL, ZEYNEP BELMA GÖLGE

Tek doz bupropion kullanımına bağlı akut distoni: Bir olgu sunumu

Süleyman DEMİR, Abdullah ATLI, MEHMET GÜNEŞ, Songül ÇATI, EŞREF AKIL, Nuralay ÇETİNKAYA

Kuzey Kıbrıs'ta ilaçla özkıyım girişimi üzerine bir araştırma: 2002-2012 yıllarının veri analizi

İpek SÖNMEZ, Abidin AKBİRGÜN, Ali BOZKURT

Hafif bilişsel bozukluk

Orhan DOĞAN

Risperidone use in preschool children with aggressive and destructive behavioral symptoms

Caner MUTLU, Özden ÜNERI ŞÜKRAN, CANAN TANIDIR, Hatice GÜNEŞ, Mazlum ÇÖPÜR, ALİ GÜVEN KILIÇOĞLU, Hilal ADALETLİ, Hamiyet İPEK, AYTEN ERDOĞAN

Kafa travması sonrası gelişen frontal lob sendromu: Olgu sunumu

BETÜL ÇEVİK, Ali YILDIRIM, DÜRDANE AKSOY, Erdal ÖZER, SEMİHA GÜLSÜM KURT

Geç yaşta başlayan çalma ve biriktirme davranışı olan olgu

Buket Belkız GÜNGÖR, Almıla İkra AKGÜL, Ersin BUDAK, İbrahim TAYMUR, Rüstem AŞKIN, Asuman ALİ

Aile bireylerinde paylaşılmış psikotik bozukluğa yol açan bir pseudologia fantastica olgusu

HALİL ÖZCAN, Atakan YUCEL, Erdem Önder SÖNMEZ